In prespecified analyses, EYLEA reduced central retinal thickness2-4
Mean Change in Central Retinal Thickness, as Measured by OCT,* at 24 Weeks From Baseline2-4,†
The results of these prespecified analyses require cautious interpretation and could represent chance findings, as multiplicity adjustment has not been applied.
Anatomic measures were not used to influence treatment decisions1
VIBRANT study design: Randomized, multicenter, double-masked, controlled study in which patients with Macular Edema following BRVO (N=181; age range: 42-94 years, with a mean of 65 years) were randomized to receive 1) EYLEA 2 mg administered every 4 weeks or 2) laser photocoagulation administered at baseline and subsequently as needed (control group).
The primary efficacy endpoint was the proportion of patients who gained ≥15 letters in best-corrected visual acuity at week 24 compared to baseline.
COPERNICUS and GALILEO study designs: Randomized, multicenter, double-masked, sham-controlled studies in patients with Macular Edema following CRVO (N=358; age range: 22-89 years, with a mean of 64 years). Patients were assigned in a 3:2 ratio to either 1) EYLEA 2 mg administered every 4 weeks (monthly) for the first 6 months or 2) sham injections (control) administered every 4 weeks (monthly) for a total of 6 injections.
In both studies, the primary efficacy endpoint was the proportion of patients who gained ≥15 letters in best-corrected visual acuity at week 24 compared to baseline.
- Optical coherence tomography.
- Last observation carried forward; full analysis set.